{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:38Z","timestamp":1781650778107,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Myocarditis, defined as inflammation of heart muscle, can be triggered by viral infection or have an autoimmune origin. In some cases, it progresses to dilated cardiomyopathy (DCM) and heart failure. The human leukocyte antigen (HLA) system is important in adaptive immunity by influencing antigen presentation and autoimmunity. This review intends to clarify the role of HLA polymorphisms in the progression, resistance, and outcomes of myocarditis and DCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Evidence indicates that HLA is linked to myocarditis and DCM through familial aggregation, myocardial HLA upregulation, circulating cardiac autoantibodies, candidate association studies, genome-wide association signals at chromosome 6p21, and transgenic models demonstrating HLA-restricted disease susceptibility. HLA alleles influence viral clearance, molecular mimicry, autoimmune priming, cytokine signaling, and pathogen-specific autoantibody production. Translation of this evidence into clinical practice has been limited by modest effect sizes, population variability, and the lack of genotype-guided therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Using HLA as a risk-stratification tool can allow more accurate surveillance and immunomodulatory strategies for myocarditis and DCM. Future research priorities should include multi-ethnic HLA studies, viral epitope mapping, integration of immune profiling, and HLA-stratified clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-026-00761-0","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:26:24Z","timestamp":1777022784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy"],"prefix":"10.1007","volume":"23","author":[{"given":"Nihit","family":"Goli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"33","key":"761_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636\u201348.","journal-title":"Eur Heart J"},{"issue":"9","key":"761_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann I, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"761_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","volume":"12","author":"A Pollack","year":"2015","unstructured":"Pollack A, et al. Viral myocarditis\u2013diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12(11):670\u201380.","journal-title":"Nat Rev Cardiol"},{"key":"761_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0065-2776(08)00604-4","volume":"99","author":"D Cihakova","year":"2008","unstructured":"Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95\u2013114.","journal-title":"Adv Immunol"},{"issue":"5","key":"761_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11886-020-01278-1","volume":"22","author":"K Bruestle","year":"2020","unstructured":"Bruestle K, et al. Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment. Curr Cardiol Rep. 2020;22(5):28.","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"761_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0002-9149(90)90815-I","volume":"65","author":"CJ Limas","year":"1990","unstructured":"Limas CJ, et al. Anti-beta-receptor antibodies in human dilated cardiomyopathy and correlation with HLA-DR antigens. Am J Cardiol. 1990;65(7):483\u20137.","journal-title":"Am J Cardiol"},{"issue":"4","key":"761_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1388-9842(02)00010-7","volume":"4","author":"AL Caforio","year":"2002","unstructured":"Caforio AL, et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4(4):411\u20137.","journal-title":"Eur J Heart Fail"},{"key":"761_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-57613-8_10","volume":"1003","author":"W Bracamonte-Baran","year":"2017","unstructured":"Bracamonte-Baran W, Cihakova D. Cardiac Autoimmunity: Myocarditis. Adv Exp Med Biol. 2017;1003:187\u2013221.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"761_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss HP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):32.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"761_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/hrt.77.6.549","volume":"77","author":"CJ McKenna","year":"1997","unstructured":"McKenna CJ, et al. Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution. Heart. 1997;77(6):549\u201352.","journal-title":"Heart"},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","volume":"31","author":"JS Blum","year":"2013","unstructured":"Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443\u201373.","journal-title":"Annu Rev Immunol"},{"key":"761_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/nyas.12134","volume":"1285","author":"JG Barin","year":"2013","unstructured":"Barin JG, Cihakova D. Control of inflammatory heart disease by CD4\u2009+\u2009T cells. Ann N Y Acad Sci. 2013;1285:80\u201396.","journal-title":"Ann N Y Acad Sci"},{"issue":"3\u20134","key":"761_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaut.2009.09.005","volume":"33","author":"V Taneja","year":"2009","unstructured":"Taneja V, David CS. Spontaneous autoimmune myocarditis and cardiomyopathy in HLA-DQ8.NODAbo transgenic mice. J Autoimmun. 2009;33(3\u20134):260\u20139.","journal-title":"J Autoimmun"},{"issue":"7","key":"761_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacbts.2021.06.003","volume":"6","author":"LT Cooper Jr","year":"2021","unstructured":"Cooper LT Jr., Cihakova D. Do Genes Influence Susceptibility to Myocarditis? JACC Basic Transl Sci. 2021;6(7):593\u20134.","journal-title":"JACC Basic Transl Sci"},{"issue":"9","key":"761_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/0002-9149(84)90088-2","volume":"53","author":"JL Anderson","year":"1984","unstructured":"Anderson JL, et al. HLA A, B and DR typing in idiopathic dilated cardiomyopathy: a search for immune response factors. Am J Cardiol. 1984;53(9):1326\u201330.","journal-title":"Am J Cardiol"},{"issue":"1","key":"761_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0167-5273(98)00336-2","volume":"68","author":"AA Harcombe","year":"1999","unstructured":"Harcombe AA, et al. HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Int J Cardiol. 1999;68(1):31\u20137.","journal-title":"Int J Cardiol"},{"issue":"4","key":"761_CR17","doi-asserted-by":"publisher","first-page":"e5131","DOI":"10.1590\/1414-431X20165131","volume":"49","author":"B Jin","year":"2016","unstructured":"Jin B, et al. HLA-DR3 antigen in the resistance to idiopathic dilated cardiomyopathy. Braz J Med Biol Res. 2016;49(4):e5131.","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"761_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.gene.2013.09.022","volume":"531","author":"S Pankuweit","year":"2013","unstructured":"Pankuweit S, et al. The HLA class II allele DQB1 0309 is associated with dilated cardiomyopathy. Gene. 2013;531(2):180\u20133.","journal-title":"Gene"},{"issue":"1","key":"761_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/08916930802258651","volume":"42","author":"I Portig","year":"2009","unstructured":"Portig I, et al. HLA-DQB1* polymorphism and associations with dilated cardiomyopathy, inflammatory dilated cardiomyopathy and myocarditis. Autoimmunity. 2009;42(1):33\u201340.","journal-title":"Autoimmunity"},{"issue":"16","key":"761_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/eurheartj\/eht251","volume":"35","author":"B Meder","year":"2014","unstructured":"Meder B, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 2014;35(16):1069\u201377.","journal-title":"Eur Heart J"},{"issue":"7","key":"761_CR21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10875-022-01372-9","volume":"42","author":"A Bolze","year":"2022","unstructured":"Bolze A, et al. Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis. J Clin Immunol. 2022;42(7):1354\u20139.","journal-title":"J Clin Immunol"},{"issue":"6","key":"761_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/eurheartj\/14.6.758","volume":"14","author":"C Hengstenberg","year":"1993","unstructured":"Hengstenberg C, et al. De novo expression of MHC class I and class II antigens on endomyocardial biopsies from patients with inflammatory heart disease and rejection following heart transplantation. Eur Heart J. 1993;14(6):758\u201363.","journal-title":"Eur Heart J"},{"issue":"19","key":"761_CR23","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1161\/CIRCULATIONAHA.108.766022","volume":"119","author":"T Yajima","year":"2009","unstructured":"Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation. 2009;119(19):2615\u201324.","journal-title":"Circulation"},{"issue":"4","key":"761_CR24","doi-asserted-by":"publisher","first-page":"e14142","DOI":"10.1111\/eci.14142","volume":"54","author":"A Aharon","year":"2024","unstructured":"Aharon A, et al. HLA binding-groove motifs are associated with myocarditis induction after Pfizer-BioNTech BNT162b2 vaccination. Eur J Clin Invest. 2024;54(4):e14142.","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"761_CR25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4049\/jimmunol.2300841","volume":"212","author":"JJ Racine","year":"2024","unstructured":"Racine JJ, et al. Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti-PD-1 Immune Checkpoint Inhibitor Cancer Therapy. J Immunol. 2024;212(8):1287\u2013306.","journal-title":"J Immunol"},{"issue":"7","key":"761_CR26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/0735-1097(90)92821-I","volume":"15","author":"AL Caforio","year":"1990","unstructured":"Caforio AL, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol. 1990;15(7):1527\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yjmcc.2017.04.003","volume":"107","author":"ME Selli","year":"2017","unstructured":"Selli ME, et al. A humanized HLA-DR4 mouse model for autoimmune myocarditis. J Mol Cell Cardiol. 2017;107:22\u20136.","journal-title":"J Mol Cell Cardiol"},{"issue":"23","key":"761_CR28","doi-asserted-by":"publisher","first-page":"13447","DOI":"10.1073\/pnas.2235552100","volume":"100","author":"JF Elliott","year":"2003","unstructured":"Elliott JF, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice. Proc Natl Acad Sci U S A. 2003;100(23):13447\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"761_CR29","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.4049\/jimmunol.172.4.2651","volume":"172","author":"JA Taylor","year":"2004","unstructured":"Taylor JA, et al. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J Immunol. 2004;172(4):2651\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"761_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1399-0039.2005.00457.x","volume":"66","author":"D Shichi","year":"2005","unstructured":"Shichi D, et al. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens. 2005;66(3):200\u20138.","journal-title":"Tissue Antigens"},{"issue":"2","key":"761_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCRESAHA.124.324674","volume":"135","author":"S Heymans","year":"2024","unstructured":"Heymans S, et al. Clinical Characteristics and Mechanisms of Acute Myocarditis. Circ Res. 2024;135(2):397\u2013411.","journal-title":"Circ Res"},{"issue":"6","key":"761_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0735-1097(87)80471-0","volume":"9","author":"A Herskowitz","year":"1987","unstructured":"Herskowitz A, et al. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains. J Am Coll Cardiol. 1987;9(6):1311\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"761_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fcvm.2019.00064","volume":"6","author":"P Blyszczuk","year":"2019","unstructured":"Blyszczuk P. Myocarditis in Humans and in Experimental Animal Models. Front Cardiovasc Med. 2019;6:64.","journal-title":"Front Cardiovasc Med"},{"key":"761_CR34","doi-asserted-by":"crossref","unstructured":"Vicenzetto C et al. Cellular Immunology of myocarditis: lights and shades-a literature review. Cells. 2024;13(24):2082.","DOI":"10.3390\/cells13242082"},{"issue":"1","key":"761_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","volume":"42","author":"MF Cusick","year":"2012","unstructured":"Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102\u201311.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"761_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12265-013-9519-3","volume":"7","author":"C Massilamany","year":"2014","unstructured":"Massilamany C, et al. Relevance of molecular mimicry in the mediation of infectious myocarditis. J Cardiovasc Transl Res. 2014;7(2):165\u201371.","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"761_CR37","doi-asserted-by":"publisher","first-page":"e1178","DOI":"10.1002\/iid3.1178","volume":"12","author":"BA Suliman","year":"2024","unstructured":"Suliman BA. Potential clinical implications of molecular mimicry-induced autoimmunity. Immun Inflamm Dis. 2024;12(2):e1178.","journal-title":"Immun Inflamm Dis"},{"issue":"14\u201315","key":"761_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.molimm.2003.11.023","volume":"40","author":"MW Cunningham","year":"2004","unstructured":"Cunningham MW. T cell mimicry in inflammatory heart disease. Mol Immunol. 2004;40(14\u201315):1121\u20137.","journal-title":"Mol Immunol"},{"issue":"6467","key":"761_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.aav3487","volume":"366","author":"C Gil-Cruz","year":"2019","unstructured":"Gil-Cruz C, et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019;366(6467):881\u20136.","journal-title":"Science"},{"issue":"12","key":"761_CR40","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/CIRCRESAHA.124.323816","volume":"134","author":"T Won","year":"2024","unstructured":"Won T, et al. Autoimmune Myocarditis, Old Dogs and New Tricks. Circ Res. 2024;134(12):1767\u201390.","journal-title":"Circ Res"},{"issue":"11","key":"761_CR41","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.4049\/jimmunol.177.11.8234","volume":"177","author":"Y Li","year":"2006","unstructured":"Li Y, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177(11):8234\u201340.","journal-title":"J Immunol"},{"key":"761_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2014.00013","volume":"5","author":"AJ Yates","year":"2014","unstructured":"Yates AJ. Theories and quantification of thymic selection. Front Immunol. 2014;5:13.","journal-title":"Front Immunol"},{"key":"761_CR43","doi-asserted-by":"publisher","first-page":"170671","DOI":"10.1016\/j.peptides.2021.170671","volume":"146","author":"I Ohigashi","year":"2021","unstructured":"Ohigashi I, Matsuda-Lennikov M, Takahama Y. Peptides for T cell selection in the thymus. Peptides. 2021;146:170671.","journal-title":"Peptides"},{"issue":"12","key":"761_CR44","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1002\/eji.200324365","volume":"33","author":"JA Borghans","year":"2003","unstructured":"Borghans JA, Noest AJ, De Boer RJ. Thymic selection does not limit the individual MHC diversity. Eur J Immunol. 2003;33(12):3353\u20138.","journal-title":"Eur J Immunol"},{"issue":"5","key":"761_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tig.2020.10.001","volume":"37","author":"P Pontarotti","year":"2021","unstructured":"Pontarotti P, et al. Self-Peptidome Variation Shapes Individual Immune Responses. Trends Genet. 2021;37(5):414\u201320.","journal-title":"Trends Genet"},{"issue":"23","key":"761_CR46","doi-asserted-by":"publisher","first-page":"e2309674121","DOI":"10.1073\/pnas.2309674121","volume":"121","author":"B Koncz","year":"2024","unstructured":"Koncz B, Balogh GM, Manczinger M. A journey to your self: The vague definition of immune self and its practical implications. Proc Natl Acad Sci U S A. 2024;121(23):e2309674121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"761_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/eurjhf\/hfr014","volume":"13","author":"M Noutsias","year":"2011","unstructured":"Noutsias M, et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail. 2011;13(6):611\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"761_CR48","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.124.323661","volume":"134","author":"D Ashour","year":"2024","unstructured":"Ashour D, et al. Exploring T Cell Receptor Repertoires in Myocardial Diseases. Circ Res. 2024;134(12):1808\u201323.","journal-title":"Circ Res"},{"issue":"7937","key":"761_CR49","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"issue":"1","key":"761_CR50","first-page":"35","volume":"10","author":"P Yan","year":"2024","unstructured":"Yan P, et al. Reconstitution of peripheral blood T cell receptor beta immune repertoire in immune checkpoint inhibitors associated myocarditis. Cardiooncology. 2024;10(1):35.","journal-title":"Cardiooncology"},{"issue":"3","key":"761_CR51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tschope","year":"2021","unstructured":"Tschope C, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169\u201393.","journal-title":"Nat Rev Cardiol"},{"issue":"9396","key":"761_CR52","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","volume":"362","author":"DC Wraith","year":"2003","unstructured":"Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;362(9396):1659\u201366.","journal-title":"Lancet"},{"issue":"5","key":"761_CR53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri.2017.143","volume":"18","author":"CA Dendrou","year":"2018","unstructured":"Dendrou CA, et al. HLA variation and disease. Nat Rev Immunol. 2018;18(5):325\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"761_CR54","doi-asserted-by":"publisher","first-page":"e26475","DOI":"10.1097\/MD.0000000000026475","volume":"100","author":"RT Bian","year":"2021","unstructured":"Bian RT, Wang ZT, Li WY. Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis. Med (Baltim). 2021;100(26):e26475.","journal-title":"Med (Baltim)"},{"issue":"3","key":"761_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/08916930109007387","volume":"34","author":"SB Felix","year":"2001","unstructured":"Felix SB, Staudt A, Friedrich GB. Improvement of cardiac function after immunoadsorption in patients with dilated cardiomyopathy. Autoimmunity. 2001;34(3):211\u20135.","journal-title":"Autoimmunity"},{"issue":"2","key":"761_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0167-5273(96)02598-3","volume":"54","author":"G Wallukat","year":"1996","unstructured":"Wallukat G, et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol. 1996;54(2):191\u20135.","journal-title":"Int J Cardiol"},{"issue":"7","key":"761_CR57","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41590-024-01862-5","volume":"25","author":"O Oyesola","year":"2024","unstructured":"Oyesola O, et al. Genetic and environmental interactions contribute to immune variation in rewilded mice. Nat Immunol. 2024;25(7):1270\u201382.","journal-title":"Nat Immunol"},{"issue":"13","key":"761_CR58","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1093\/cvr\/cvaf165","volume":"121","author":"J Noonan","year":"2025","unstructured":"Noonan J, et al. CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. Cardiovasc Res. 2025;121(13):2082\u201394.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"761_CR59","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes J, et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823\u201336.","journal-title":"Nat Rev Immunol"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00761-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00761-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:39:40Z","timestamp":1781649580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00761-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00761-0","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Tang has served as a consultant for Cardiol Therapeutics, CardiaTec Biosciences, Alleviant Medical, AstraZeneca, Salubris Biotherapeutics, BioCardia inc, Tenax Therapeutics, BridgeBio Pharma, Vasa Therapeutics, and has received honorarium from Springer and Belvoir Media Group. All other authors have no relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}